Sarepta Therapeutics (SRPT) snapped a five-day winning streak, falling 4% ahead of its Q4 earnings. Wall Street anticipates revenue of $391 million amid rising short interest, which hit a six-month high. Despite bearish positioning, institutional support remains strong, with BlackRock increasing its stake to over 14 million shares as the fourth quarter report approaches.